TREM2, CD33, and Microglial Lipid-Sensing Innate Immunity

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a 230-amino-acid single-pass transmembrane innate immune receptor encoded on human chromosome 6p21.1 (4.7 kb, 5 exons) and expressed inside the central nervous system exclusively by microglia, where it senses anionic phospholipids, sulfatides, and lipidated Apolipoprotein E (APOE) and Clusterin (CLU / APOJ) complexes exposed on damaged myelin, apoptotic neurons, and amyloid-β (Aβ) plaques. Because the short cytoplasmic tail of TREM2 lacks intrinsic signaling motifs, ligand engagement induces electrostatic pairing within the transmembrane domain (Lys186) with the homodimeric adapter TYRO Protein Tyrosine Kinase-Binding Protein (TYROBP, also known as DAP12 on Chr19q13.12), whose cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) recruit Spleen Tyrosine Kinase (SYK) and Phospholipase C Gamma 2 (PLCG2) to drive microglial chemotaxis, metabolic activation, and phagocytic compaction of amyloid plaques.

Opposing this activating TREM2–DAP12–SYK–PLCG2 axis is CD33 (Siglec-3), a 364-amino-acid sialic-acid-binding immunoglobulin-like lectin encoded on Chr19q13.41 whose cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) recruit the protein tyrosine phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11) to dephosphorylate SYK and DAP12, suppressing microglial phagocytosis. Human population genetics demonstrates that rare loss-of-function variants in TREM2—most notably Arg47His (R47H, rs75932628)—elevate late-onset Alzheimer disease (LOAD) risk 3.0- to 4.5-fold (comparable in effect size to a single APOE ε4 allele), whereas a rare hypermorphic variant in downstream PLCG2 (Pro522Arg, rs72824905) and a common Exon 2-skipping polymorphism in CD33 (rs3865444 / rs12459419) confer significant protection against Alzheimer dementia and promote cognitive longevity.

The Basic Pliancy Surface and the Arg47His Risk Mutation

Mature human TREM2 consists of an extracellular V-type immunoglobulin (IgV) domain (residues 19–134), a flexible stalk region (residues 135–174), a single transmembrane α-helix (residues 175–195) containing a positively charged Lys186 residue that forms an intramembrane salt bridge with Asp50 on each DAP12 monomer, and a 35-residue cytoplasmic tail. X-ray crystallographic structures (1.8–2.2 Å resolution) of the TREM2 IgV ectodomain reveal two functionally distinct surface patches at its apex:

1. The Basic Electropositive Ligand-Binding Surface: Composed of Arg47, Arg62, His67, and Arg77 across the CDR1 and CDR2 loops, which creates a positively charged patch that binds polyanionic ligands including phosphatidylserine (PS), phosphatidylethanolamine (PE), cardiolipin, sulfatides, bacterial lipopolysaccharides, nucleic acids, and lipidated APOE/CLU lipoproteins.
2. The Apical Hydrophobic Patch: Formed by aromatic and aliphatic side chains (Trp44, Leu69, Trp70, Phe74, Leu89) that insert directly into exposed acyl chains of damaged lipid bilayers and oligomeric Aβ42 protofibrils.

In the Alzheimer disease risk variant TREM2 Arg47His (R47H, c.140G>A; minor allele frequency ~0.2–0.6% in Europeans, OR = 3.1–4.5) and the related variant Arg62His (R62H, OR ≈ 1.4–1.7), substitution of the long guanidinium side chain of Arg47 with histidine disrupts hydrogen-bonding networks across the CDR2 loop (residues 66–77), collapsing the basic phospholipid-binding pocket without causing global protein misfolding. By contrast, homozygous recessive nonsense or misfolding mutations inside the hydrophobic β-sandwich core of the IgV domain (Tyr38Cys, Thr66Met, Val126Gly, or homozygous loss of TYROBP) abolish cell-surface expression altogether, causing Nasu–Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, PLOSL), characterized by pathological bone cysts and fatal presenile frontotemporal demyelination in the fourth decade of life.

Stalk Cleavage by ADAM10/ADAM17 and Soluble TREM2 (sTREM2)

Signaling duration of full-length membrane TREM2 is terminated by proteolytic ectodomain shedding within the stalk region by ADAM10 and ADAM17 (TACE), which cleave the peptide bond between His157 and Ser158, releasing soluble TREM2 (sTREM2) into the interstitial fluid and cerebrospinal fluid (CSF) while leaving a membrane-tethered C-terminal stub degraded by γ-secretase. A rare coding mutation situated directly at the scissile bond, His157Tyr (H157Y, rs2234255), accelerates ADAM10/ADAM17 shedding by >2.5-fold, depleting cell-surface signaling-competent TREM2 and increasing Alzheimer disease risk (OR ≈ 4.7 in Han Chinese and European cohorts). Conversely, therapeutic agonistic monoclonal antibodies such as AL002 and 4D9 bind the stalk region immediately N-terminal to His157, sterically blocking ADAM10/ADAM17 cleavage while cross-linking surface TREM2 dimers to drive SYK phosphorylation.

Two-Step Transition from Homeostatic to Stage 2 DAM

Single-cell RNA sequencing (scRNA-seq) of aging and Alzheimer brains demonstrates that microglia transition from a resting homeostatic state (expressing P2RY12, TMEM119, CX3CR1, and SALL1) into Disease-Associated Microglia (DAM) via a sequential two-stage transcriptional checkpoint:

1. Stage 1 DAM (TREM2-Independent Intermediate State): Triggered by initial sensing of neuronal damage or small Aβ seeds, microglia downregulate homeostatic check-point genes (P2RY12, CX3CR1, TMEM119) and upregulate APOE, TYROBP (DAP12), B2M, and FTH1.
2. Stage 2 DAM (TREM2–SYK–PLCG2-Dependent Phagocytic State): Engagement of TREM2 by APOE-coated amyloid plaques phosphorylates the dual tyrosines of DAP12 ITAM motifs (Tyr91 and Tyr102) via SRC-family kinases (LYN/HCK), creating a high-affinity docking site for the tandem SH2 domains of SYK (Tyr525/526 activation loop). simultaneously, TREM2 pairs with DAP10 (HCST) to recruit Phosphoinositide 3-Kinase (PI3K p85/p110δ), converting PIP2 into PIP3 (opposed by the lipid phosphatase INPP5D/SHIP1) to activate AKT–mTORC1 and HIF-1α glycolysis, providing ATP and NADPH for actin-driven phagocytosis. SYK phosphorylates the scaffolding adaptors BLNK/LAT2 and activates PLCG2, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) (triggering endoplasmic reticulum Ca2+ release and NFAT nuclear translocation) and diacylglycerol (DAG) (activating PKC and CARD9–BCL10–MALT1 NF-κB signaling). This cascade unlocks full Stage 2 DAM expression of LPL (lipoprotein lipase), CST7, SPP1 (osteopontin), ITGAX (CD11c), CLEC7A (Dectin-1), and lysosomal cholesterol exporters ([ABCA1 and ABCA7](/wiki/abca1-abca7-and-lrp1)).

Microglial Plaque Barrier Compaction and Protective PLCG2 P522R

In wild-type TREM2 brains, Stage 2 DAM microglia extend dynamic processes that envelop nascent Aβ plaques in a tight physical barrier, compacting diffuse, neurotoxic protofibrillar Aβ42 halos into dense-core inert plaques and shielding surrounding axons from dystrophic neurite swelling and MAPT (tau) hyperphosphorylation. In TREM2 R47H carriers or TREM2-deficient mice, microglia stall at Stage 1 DAM and fail to cluster around plaques, leaving uncompacted filamentous Aβ fibrils exposed to adjacent neurites and accelerating tau seeding.

Conversely, the rare missense variant PLCG2 Pro522Arg (P522R, rs72824905) resides inside the autoinhibitory linker connecting the SH2 and SH3 domains of PLCG2. Substituting rigid proline with positively charged arginine partially relieves autoinhibition upon TREM2–SYK stimulation—enhancing PIP2 hydrolysis and Ca2+ mobilization by 25–40% without causing constitutive baseline hyperactivation (unlike severe gain-of-function PLCG2 mutations in the SH2/C2 domains that cause autoinflammatory PLAID/APLAID syndromes). Carriers of PLCG2 P522R exhibit a 32% reduction in Alzheimer disease risk (OR = 0.68), slower conversion from mild cognitive impairment to dementia, and increased likelihood of surviving past age 100 with intact cognition.

Sialic Acid Recognition and Exon 2 Skipping (rs3865444 / rs12459419)

Whereas TREM2 accelerates microglial phagocytosis, CD33 (Siglec-3) acts as an inhibitory checkpoint receptor when engaged by α2-3- and α2-6-linked sialic acid glycoproteins and gangliosides (GD1a, GT1b) on host cell surfaces (and sialylated plaques). Sialic acid binding to the N-terminal extracellular IgV domain (encoded by Exon 2, specifically via Arg119) triggers tyrosine phosphorylation of the cytoplasmic ITIM (Tyr340) and ITIM-like (Tyr358) motifs, recruiting SHP-1 and SHP-2 to dephosphorylate DAP12 and SYK.

In human LOAD GWAS, the protective minor allele of rs3865444(A) in the CD33 promoter sits in complete linkage disequilibrium (r2 = 0.99) with the functional causal variant rs12459419(T) (c.41C>T, Ala14Val) located 4 bp inside the 5′ splice site of Exon 2. The rs12459419(T) transition disrupts an exonic splicing enhancer (SRSF2 binding site), causing the spliceosome to skip Exon 2 in ~35–70% of CD33 transcripts. The resulting short isoform (CD33m or D2-CD33) lacks the entire ligand-binding IgV domain and is retained inside intracellular peroxisomes/endosomes rather than trafficking to the plasma membrane, releasing the inhibitory brake on TREM2-dependent Aβ clearance.

Why does CSF soluble TREM2 (sTREM2) peak during mild cognitive impairment and predict slower decline?

Cerebrospinal fluid sTREM2 is produced primarily via ADAM10/ADAM17 proteolytic shedding of cell-surface TREM2 on activated Stage 2 DAM microglia that have successfully proliferated and engaged Aβ plaques and tau-bearing neurons. Consequently, elevated CSF sTREM2 in Aβ-positive individuals serves as a quantitative biomarker of robust microglial target engagement and barrier compaction, correlating with attenuated hippocampal atrophy and slower longitudinal cognitive decline at any given amyloid and tau burden.

How does TREM2 function differ between early amyloid seeding and late-stage tauopathy?

During the initial 15–20 year amyloid accumulation phase, TREM2 activation is protective because microglial barrier formation compacts diffuse Aβ protofibrils and limits peri-plaque dystrophic neurite damage. In late-stage tauopathy (Braak stages V–VI), however, chronic hyperactivation of TREM2–APOE4 signaling in senescent, lipid-droplet-laden microglia can stimulate inflammasome (NLRP3) activation, complement (C1q/C3) opsonization of viable synapses, and TNF-α/IL-1α secretion that exacerbates neuronal loss.

Why does INPP5D (SHIP1) act as an opposing genetic regulator of TREM2?

INPP5D encodes SH2-containing inositol 5′-phosphatase 1 (SHIP1), which binds phosphorylated ITIM motifs (and competed ITAM motifs on DAP12) to hydrolyze the 5′-phosphate of PIP3 back to PI(3,4)P2. By depleting PIP3 generated by TREM2–DAP10–PI3K, SHIP1 prevents membrane recruitment of the PH domains of PLCG2 and AKT, dampening microglial phagocytic activation.

1. Guerreiro, R., Wojtas, A., Bras, J., et al. (2013). "TREM2 variants in Alzheimer's disease." New England Journal of Medicine, 368(2), 117–127. https://doi.org/10.1056/NEJMoa1211851
2. Keren-Shaul, H., Spinrad, A., Weiner, A., et al. (2017). "A unique microglia type associated with restricting development of Alzheimer's disease." Cell, 169(7), 1276–1290.e17. https://doi.org/10.1016/j.cell.2017.05.018
3. Sims, R., van der Lee, S. J., Naj, A. C., et al. (2017). "Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease." Nature Genetics, 49(9), 1373–1384. https://doi.org/10.1038/ng.3916
4. Ulland, T. K., Song, W. M., Huang, S. C.-C., et al. (2017). "TREM2 maintains microglial metabolic fitness in Alzheimer's disease." Cell, 170(4), 649–663.e13. https://doi.org/10.1016/j.cell.2017.07.023